MS275 enhances cytotoxicity induced by 5-fluorouracil in the colorectal cancer cells

European Journal of Pharmacology

Volumn 627, Issue 1-3, 2010, Pages 26-32

  Flis, Sylwia ^a   Gnyszka, Agnieszka ^a   Flis, Krzysztof ^b   Spławiński, Jacek ^a  

^a NATIONAL MEDICINES INSTITUTE   (Poland)

^b INSTITUTE OF BIOCHEMISTRY AND BIOPHYSICS   (Poland)

Author keywords

5 fluorouracil; Apoptosis; Colorectal cancer; MS275; SBHA; Synergism

Indexed keywords

FLUOROURACIL; HISTONE DEACETYLASE INHIBITOR; N (2 AMINOPHENYL) 4 (3 PYRIDINYLMETHOXYCARBONYLAMINOMETHYL)BENZAMIDE; SUBERIC BISHYDROXAMIC ACID; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; COLORECTAL CANCER; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DRUG POTENTIATION; HUMAN; HUMAN CELL; MITOCHONDRIAL MEMBRANE POTENTIAL; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BENZAMIDES; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; COLORECTAL NEOPLASMS; DRUG SYNERGISM; FLUOROURACIL; HISTONE DEACETYLASE INHIBITORS; HUMANS; HYDROXAMIC ACIDS; MEMBRANE POTENTIAL, MITOCHONDRIAL; PYRIDINES;

EID: 73449126835     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2009.10.033     Document Type: Article

References (18)

1. Carew J., Giles F., and Nawrocki S. Histone deacetylase inhibitors: mechanisms of cell death and promise in combination cancer therapy. Cancer Lett. 269 (2008) 7-17
2. Chou T.C., and Talalay P. Analysis of combined drug effects: a new look at a very old problem. Trends Pharmacol. Sci. 4 (1983) 450-454
3. Chou T.C., and Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv. Enzyme Regul. 22 (1984) 27-55
4. Di Gennaro E., Bruzzese F., Caraglia M., Abruzzese A., and Budillon A. Acetylation of proteins as novel target for antitumor therapy: review article. Amino Acids 26 (2004) 435-441
5. Gessner P.K. Isobolographic analysis of interactions: an update on applications and utility. Toxicology 105 (1995) 161-179
6. Hellebrekers D.M., Griffioen A.W., and van Engeland M. Dual targeting of epigenetic therapy in cancer. Biochim. Biophys. Acta. 1775 (2007) 76-91
7. IARC TP53 Mutation Database, http://www-p53.iarc.fr/CellLineCriteria.asp.
8. Kannan K., and Jain S.K. Oxidative stress and apoptosis. Pathophysiology 7 (2000) 153-163
9. Liu T., Kuljaca S., Tee A., and Marshall G.M. Histone deacetylase inhibitors: multifunctional anticancer agents. Cancer Treat. Rev. 32 (2006) 157-165
10. Maggio S.C., Rosato R.R., Kramer L.B., Dai Y., Rahmani M., Paik D.S., Czarnik A.C., Payne S.G., Spiegel S., and Grant S. The histone deacetylase inhibitor MS-275 interacts synergistically with fludarabine to induce apoptosis in human leukemia cells. Cancer Res. 64 (2004) 2590-2600
11. Mahyar-Roemer M., Katsen A., Mestres P., and Roemer K. Resveratrol induces colon tumor cell apoptosis independently of p53 and precede by epithelial differentiation, mitochondrial proliferation and membrane potential collapse. Int. J. Cancer 94 (2001) 615-622
12. Martirosyan A., Leonard S., Shi X., Griffith B., Gannett P., and Strobl J. Actions of a histone deacetylase inhibitor NSC3852 (5-nitroso-8-quinolinol) link reactive oxygen species to cell differentiation and apoptosis in MCF-7 human mammary tumor cells. J. Pharmacol. Exp. Ther. 317 (2006) 546-552
13. Peters G.J., Van Der Wilt C.L., Van Moorsel C.J.A., Kroep J.R., Bergman A.M., and Ackland S.P. Basis for effective combination cancer chemotherapy with antimetabolites. Pharmacol. Ther. 87 (2000) 227-253
14. WAF1 expression and gene-associated histone acetylation. Proc. Natl. Acad. Sci. U. S. A. 97 (2000) 10014-10019
15. CIP1/WAF1 1. Cancer Res. 63 (2003) 3637-3645
16. Ruefli A.A., Ausserlechner M.J., Bernhard D., Sutton V.R., Tainton K.M., Kofler R., Smyth M.J., and Johnstone R.W. The histone deacetylase inhibitor and chemotherapeutic agent suberoylanilide hydroxamic acid (SAHA) induces a cell death pathway characterized by cleavage of Bid and production of reactive oxygen species. Proc. Natl. Acad. Sci. U. S. A. 98 (2001) 10833-10838
17. Zhang X.D., Gillespie S.K., Borrow J.M., and Hersey P. The histone deacetylase inhibitor suberic bishydroxamate: a potentialsensitizer of melanoma to TNF-related apoptosis-inducing ligand (TRAIL) induced apoptosis. Biochem. Pharmacol. 66 (2003) 1537-1545
18. Zhang X.D., Gillespie S.K., Borrow J.M., and Hersey P. The histone deacetylase inhibitor suberic bishydroxamate regulates the expression of multiple apoptotic mediators and induces mitochondria-dependent apoptosis of melanoma cell. Mol. Cancer Ther. 3 (2004) 425-435